Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. - Wikidata - wikimedia - TriplyDB

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

http://www.wikidata.org/entity/Q46112189

about

The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease The Promise and Challenge of Therapeutic MicroRNA Silencing in Diabetes and Metabolic Diseases Hypertriglyceridemia and Cardiovascular Diseases: Revisited The year in cardiology 2015: prevention New Era of Lipid-Lowering Drugs The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers The Role of Emerging Risk Factors in Cardiovascular Outcomes The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.Genetics of coronary artery disease: discovery, biology and clinical translation.The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver.Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update.Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy Metabolic Characterization of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipase-Independent Effects.An APOC3 3'UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site.A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.Gene-targeting pharmaceuticals for single-gene disorders.Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity.Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.Experimental Biology for the Identification of Causal Pathways in Atherosclerosis.Cardiovascular Gene Therapy: Past, Present, and Future.The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities.Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia.Targeting ApoC-III to Reduce Coronary Disease Risk.Triglyceride Treatment in the Age of Cholesterol Reduction.Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma.Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.Lomitapide for the treatment of hypertriglyceridemia.Hypertriglyceridaemia and risk of coronary artery disease.PPAR-α agonists are still on the rise: an update on clinical and experimental findings.

P2860

Q26748869-E36B56E9-6AF6-4047-8532-F42264D2B4D1 Q26750496-AA0B7FED-A539-4623-98D1-7C858F88BE7F Q26750954-1A98B367-AC07-4C6F-A250-18E45B06E7F8 Q28072221-4999D70A-FD33-46FA-BCBB-332E4229BAF7 Q28072298-944C86C2-7AD8-4A8D-8C8D-81ACB66C92CE Q28072835-B4C8B5E8-C94B-4A98-9C08-67996677FE3C Q28077776-8FF62449-C6C6-49DA-976C-A66242D28518 Q28821280-7A05A467-500B-4853-BC70-D61F5A57DD1C Q30234550-2D0E0EF0-9D39-427B-AB01-378248DBE645 Q33438876-4E1AA604-4E8F-4FD2-A458-E45FA382DA81 Q34551430-FEA053A7-418D-41B6-B789-782B7D1E12A7 Q34553141-4C1DD3CD-55B4-4206-B40F-0EEA1CB620F0 Q35860314-029AC61D-3CAD-4FFB-A7F8-21D33FCBAC17 Q36254032-1AEB6C0C-1876-46A9-9034-A691705E6DD1 Q36617508-42D8677D-533F-4922-A61C-A2C6E0C09639 Q36731776-CF27CA03-1FC2-4D89-9BB5-F6CAF9E4891C Q36775577-1B728C0B-1361-4A5D-83C3-B8003631ED0A Q36820247-065D1BDB-14C4-4018-AB2B-2727C79DD44C Q36851336-ADE0C054-66A4-4CFA-BDC5-5E9BFA28A731 Q36935534-7DC80A4C-3C17-46BE-AC32-D083F80F0FE3 Q37036336-FA6196A4-F19A-487E-B5DF-5A7D9250BBE6 Q37254242-3958F0EA-F8A1-4EE2-9592-DEE919BC9679 Q38616263-3EE3F430-D4AC-415A-A92B-F293EFA2ECF3 Q38656342-956B8F90-D989-4128-8C45-C36B49E5096B Q38682093-DD35BDE5-CD51-4212-82F4-A6AED15AA9AC Q38707328-1A2DF8BD-A8B9-4CFB-87B5-FA4B4F00A103 Q38723704-F2312862-3D17-42C3-BBE6-F06BD5472B0F Q38733395-B7D53187-E58E-41BE-BDCD-F2BCDD1F7DE5 Q38764871-C5373AF9-373F-4936-81DF-42DE2542696F Q38780996-F89CBA33-72DD-42EA-A880-A7180BC102A2 Q38839105-BB1250B7-8242-4F84-979A-AA0722C8FFA8 Q38842531-8BF29EC6-845B-41BC-AC82-0BC9FDC86432 Q38850010-99395600-78C6-439F-AAC5-E18C70A40203 Q38904497-67A9FBD8-CEC5-43AA-BC59-C2EC28ADDEDD Q38932760-56E92E95-FCF6-4CCC-827C-60B4232152C0 Q38972636-49227BF4-DF3A-4E84-8E11-083F5E544E31 Q38988355-80405C73-6723-4F65-BCF1-A4A77C4C4071 Q38992251-EAA3889A-6FB8-4990-9A1B-F907FCFD342C Q39181612-3FF1615C-EF43-471D-A286-FE7AB44AE59A Q39200940-5486D8EE-BCF6-4AC7-96FE-64CE3FF05B33

P2860

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

http://www.wikidata.org/entity/Q46112189

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

@en

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

@nl

type

label

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

@en

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

@nl

prefLabel

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

@en

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

@nl

P1433

Q46112189-9CE42278-71AC-4026-BBDB-C8DDC067FA21

P1476

Q46112189-F336DF6F-04C2-43BE-96EC-B4953A6CCE81

P2093

Q46112189-094D1034-81A8-4153-87CE-03DDC6002305

Q46112189-13ED4E96-A8A7-4941-8212-8DB996032EC2

Q46112189-15441917-4A2E-43BD-A690-D42189D1FD50

Q46112189-1F6C3EAB-CD38-42E9-A174-C085A267B5D5

Q46112189-2B0E3F93-682B-4DD1-A3AA-8D5543746A38

Q46112189-53397321-172F-44B2-9072-3FCB17FAF165

Q46112189-83C0A7EB-34E7-4641-9CF3-4737E3A307F3

Q46112189-9AA0BA78-DDE0-4F4E-AFA7-B84091F51A65

Q46112189-9DCC87A2-D40C-4B81-A144-2892BCAF77C9

Q46112189-A717F74A-B93D-428B-9575-F0E12D8AE864

P304

Q46112189-B2F28ADA-1963-446B-868B-A426A8CF0896

P31

Q46112189-0F36D762-63C0-4103-882B-7330D4E9C465

P356

Q46112189-41A6C218-6B89-4E28-9216-C38C804AB413

P407

Q46112189-48DE3F92-428F-4A3A-A084-D490CC7A1A6A

P433

Q46112189-D69BF205-8763-46BA-B6E9-8FCECEDD3F2F

P478

Q46112189-13201E64-0C48-405F-B857-728E7B5558ED

P50

Q46112189-E207518D-18A0-481D-8E5C-1916C7396F3E

P577

Q46112189-059DD5F3-5970-4583-A2CB-A8D89553DB15

P698

Q46112189-7908B89E-5344-438B-B906-2A527174608F

P356

P1433

The New England Journal of Medicine

P1476

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

@en

P2093

Brenda F Baker

http://www.w3.org/2001/XMLSchema#string

Daniel Gaudet

http://www.w3.org/2001/XMLSchema#string

Diane Brisson

http://www.w3.org/2001/XMLSchema#string

John D Brunzell

http://www.w3.org/2001/XMLSchema#string

John J P Kastelein

http://www.w3.org/2001/XMLSchema#string

Karine Tremblay

http://www.w3.org/2001/XMLSchema#string

Mark J Graham

http://www.w3.org/2001/XMLSchema#string

Nicholas J Viney

http://www.w3.org/2001/XMLSchema#string

Richard S Geary

http://www.w3.org/2001/XMLSchema#string

Rosanne M Crooke

http://www.w3.org/2001/XMLSchema#string

P304

438-447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1400283

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

Joseph L Witztum

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26222559

http://www.w3.org/2001/XMLSchema#string